SCHEMBL5166808

SCHEMBL5166808

NC(=O)c1c(Cl)c2ccccc2[nH]c1=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.56
TDP1 Q9NUW8 1/20 0.56
MEN1 O00255 6/20 0.50
KMT2A Q03164 6/20 0.50
ALDH1A1 P00352 4/20 0.50
HSD17B10 Q99714 2/20 0.50
HPGD P15428 1/20 0.50
LMNA P02545 3/20 0.48
MAPT P10636 3/20 0.47
IDE P14735 1/20 0.47
MPI P34949 1/20 0.47
CACNA1B Q00975 1/20 0.47
APBA1 Q02410 1/20 0.47
TNKS O95271 1/20 0.47
CYP1A2 P05177 1/20 0.47
PARP1 P09874 1/20 0.47
GPR3 P46089 1/20 0.47
BLM P54132 1/20 0.47
PMP22 Q01453 1/20 0.47
PARP15 Q460N3 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31146399 1.00 KDM4E (0.56) KDM4ETDP1MEN1KMT2AALDH1A1
SCHEMBL13997679 0.85 KDM4E (0.72) KDM4ETDP1MEN1KMT2AALDH1A1
SCHEMBL1228041 0.81 KDM4E (0.62) KDM4ETDP1MEN1KMT2AALDH1A1
SCHEMBL1621884 0.81 KDM4E (0.68) KDM4ETDP1MEN1KMT2AALDH1A1
SCHEMBL8930304 0.80 DAO (0.60) KDM4ETDP1MEN1KMT2AALDH1A1
SCHEMBL1621957 0.80 KDM4E (0.69) KDM4ETDP1MEN1KMT2AALDH1A1
SCHEMBL2730936 0.77 MAP2 (0.60) KDM4EMEN1KMT2AALDH1A1HPGD
SCHEMBL30601629 0.77 MAP2 (0.60) KDM4EMEN1KMT2AALDH1A1HPGD
SCHEMBL5280341 0.77 KDM4E (0.56) KDM4ETDP1MEN1KMT2AALDH1A1
SCHEMBL5528637 0.76 KDM4E (0.59) KDM4ETDP1MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1224172-B1 DRUGS FOR THE TREATMENT OF MALIGNANT TUMOURS ACTIVE BIOTECH AB (SE) 2007-04-04 EP claimed
CN-1589264-A Method for the treatment of malignant tumours ACTIVE BIOTECH AB (SE) 2005-03-02 CN claimed
EP-1224172-A1 DRUGS FOR THE TREATMENT OF MALIGNANT TUMOURS Active Biotech AB (SE) 2002-07-24 EP claimed
US-6395750-B1 Includes laquinimod, N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxo-quinoline-3-carboxamide and its salts; breat or prostate cancer ACTIVE BIOTECH AB (SE) 2002-05-28 US claimed
WO-2001030758-A1 DRUGS FOR THE TREATMENT OF MALIGNANT TUMOURS ACTIVE BIOTECH AB (SE) 2001-05-03 WO claimed
CN-100390148-C Method for the treatment of malignant tumours ACTIVE BIOTECH AB (SE) 2008-05-28 CN disclosed
EP-1224172-B1 DRUGS FOR THE TREATMENT OF MALIGNANT TUMOURS ACTIVE BIOTECH AB (SE) 2007-04-04 EP disclosed
CN-1589264-A Method for the treatment of malignant tumours ACTIVE BIOTECH AB (SE) 2005-03-02 CN disclosed
EP-1224172-A1 DRUGS FOR THE TREATMENT OF MALIGNANT TUMOURS Active Biotech AB (SE) 2002-07-24 EP disclosed
US-6395750-B1 Includes laquinimod, N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxo-quinoline-3-carboxamide and its salts; breat or prostate cancer ACTIVE BIOTECH AB (SE) 2002-05-28 US disclosed
WO-2001030758-A1 DRUGS FOR THE TREATMENT OF MALIGNANT TUMOURS ACTIVE BIOTECH AB (SE) 2001-05-03 WO disclosed